Literature DB >> 22223237

Adjunctive and alternative approaches to current reperfusion therapy.

Andrew D Barreto1, Andrei V Alexandrov.   

Abstract

BACKGROUND AND
PURPOSE: Current ischemic stroke reperfusion therapy consists of intravenous thrombolysis given in eligible patients after review of a noncontrast CT scan and a time-based window of opportunity. Rapid clot lysis has a strong association with clinical improvement but remains incomplete in many patients. This review appraises novel adjunctive or alternative approaches to current reperfusion strategies being tested in all trial phases. Summary of Review- Alternative approaches to current reperfusion therapy can be separated into 4 main categories: (1) combinatory approaches with other drugs or devices; (2) novel systemic thrombolytic agents; (3) endovascular medical or mechanical reperfusion treatments; and (4) noninvasive or minimally invasive methods to augment cerebral blood flow and alleviate intracranial blood flow steal.
CONCLUSIONS: Reperfusion treatments must be provided as fast as possible in patients most likely to benefit. Patients who fail to rapidly reperfuse may benefit from other strategies that maintain collateral flow or protect tissue at risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22223237      PMCID: PMC3268680          DOI: 10.1161/STROKEAHA.111.617902

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  50 in total

1.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

2.  A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.

Authors:  G R Thomas; H Thibodeaux; C J Errett; J M Badillo; B A Keyt; C J Refino; J A Zivin; W F Bennett
Journal:  Stroke       Date:  1994-10       Impact factor: 7.914

3.  A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.

Authors:  I K Jang; D F Brown; R P Giugliano; H V Anderson; D Losordo; J C Nicolau; O P Dutra; O Bazzino; V M Viamonte; R Norbady; A S Liprandi; T J Massey; R Dinsmore; R P Schwarz
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

4.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.

Authors:  E M Ohman; N S Kleiman; G Gacioch; S J Worley; F I Navetta; J D Talley; H V Anderson; S G Ellis; M D Cohen; D Spriggs; M Miller; D Kereiakes; S Yakubov; M M Kitt; K N Sigmon; R M Califf; M W Krucoff; E J Topol
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

5.  In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.

Authors:  I K Jang; H K Gold; R C Leinbach; J T Fallon; D Collen
Journal:  Circ Res       Date:  1990-12       Impact factor: 17.367

6.  Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.

Authors:  Marian T Nakada; Michael O Montgomery; Mark A Nedelman; J Luis Guerrero; Sidney A Cohen; Elliot S Barnathan; Robert E Jordan
Journal:  J Vasc Interv Radiol       Date:  2004-02       Impact factor: 3.464

7.  Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model.

Authors:  H Kawai; K Umemura; M Nakashima
Journal:  Jpn J Pharmacol       Date:  1995-10

8.  Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study.

Authors:  Marian P LaMonte; Marshall L Nash; David Z Wang; Andrew R Woolfenden; John Schultz; Marcie J Hursting; Philip M Brown
Journal:  Stroke       Date:  2004-05-20       Impact factor: 7.914

9.  Ancrod for the treatment of acute ischemic brain infarction. The Ancrod Stroke Study Investigators.

Authors: 
Journal:  Stroke       Date:  1994-09       Impact factor: 7.914

10.  Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy.

Authors:  A Basinski; C D Naylor
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

View more
  24 in total

1.  Multimodal Computed Tomography Based Definition of Cerebral Imaging Profiles for Acute Stroke Reperfusion Therapy (CT-DEFINE): Results of a Prospective Observational Study.

Authors:  K Barlinn; J Seibt; K Engellandt; J Gerber; V Puetz; J Kepplinger; O Wunderlich; L-P Pallesen; U Bodechtel; R Koch; R von Kummer; I Dzialowski
Journal:  Clin Neuroradiol       Date:  2014-08-23       Impact factor: 3.649

2.  Intra-arterial therapy as a rescue strategy after clinically failed intravenous thrombolysis may increase the likelihood of a good outcome in patients with severe ischaemic stroke. A retrospective two centre study.

Authors:  Federico Menetti; Luca Verganti; Andrea Zini; Stefano Vallone; Paolo Carpeggiani; Tommy Andersson
Journal:  Interv Neuroradiol       Date:  2014-06-17       Impact factor: 1.610

Review 3.  Beyond the time window of intravenous thrombolysis: standing by or by stenting?

Authors:  Xinfeng Liu
Journal:  Interv Neurol       Date:  2012-05

Review 4.  Changing Management of Acute Ischaemic Stroke: the New Treatments and Emerging Role of Endovascular Therapy.

Authors:  Hamed Asadi; David Williams; John Thornton
Journal:  Curr Treat Options Neurol       Date:  2016-05       Impact factor: 3.598

5.  Adjunctive medical therapies for acute stroke thrombolysis: is there a CLEAR-ER choice?

Authors:  Andrew D Barreto; Claudia Pedroza; James C Grotta
Journal:  Stroke       Date:  2013-07-25       Impact factor: 7.914

6.  Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.

Authors:  Madhuvanthi A Kandadai; Jason M Meunier; Kimberley Hart; Christy K Holland; George J Shaw
Journal:  Transl Stroke Res       Date:  2014-11-20       Impact factor: 6.829

7.  Guided longer pulses from a diagnostic ultrasound and intraclot microbubble enhanced catheter-directed thrombolysis in vivo.

Authors:  Shunji Gao; Qiong Zhu; Xiaoxiao Dong; Zhong Chen; Zheng Liu; Feng Xie
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

8.  CLOTBUST-hands free: initial safety testing of a novel operator-independent ultrasound device in stroke-free volunteers.

Authors:  Kristian Barlinn; Andrew D Barreto; April Sisson; David S Liebeskind; Mark E Schafer; John Alleman; Limin Zhao; Loren Shen; Luis F Cava; Mohammad H Rahbar; James C Grotta; Andrei V Alexandrov
Journal:  Stroke       Date:  2013-04-18       Impact factor: 7.914

9.  Sonothrombolysis in ischemic stroke.

Authors:  Kristian Barlinn; Andrei V Alexandrov
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

10.  Outcomes following sonothrombolysis in severe acute ischemic stroke: subgroup analysis of the CLOTBUST trial.

Authors:  Kristian Barlinn; Georgios Tsivgoulis; Andrew D Barreto; John Alleman; Carlos A Molina; Robert Mikulik; Maher Saqqur; Andrew M Demchuk; Peter D Schellinger; George Howard; Andrei V Alexandrov
Journal:  Int J Stroke       Date:  2014-07-31       Impact factor: 5.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.